Ici-related Myositis

Blocking PD-1, PD-L1, or CTLA-4 removes inhibitory signals that normally restrain T-cell activity. In some patients, this heightened immune activation becomes misdirected toward skeletal muscle, producing inflammation and tissue injury rather than remaining focused on tumor cells. This mechanism explains why muscle toxicity can emerge as an immune-related adverse event during cancer treatment.

Rapidly progressive weakness is particularly important because the syndrome may extend beyond ordinary muscle discomfort. Difficulty swallowing or breathing suggests involvement of functions essential for nutrition or respiration, while coexisting myocarditis or neuromuscular complications can raise risk further. These overlapping features make severity assessment more important than relying on muscle pain alone.

Creatine kinase elevation provides a biochemical signal of muscle injury and can support clinical concern when weakness or pain develops. Its significance is greatest when interpreted alongside the speed of symptom progression and functional problems, such as swallowing or breathing difficulty. The combination can help clinicians recognize a potentially serious presentation rather than treating symptoms as nonspecific.

Evaluation should begin promptly when compatible symptoms appear during immune checkpoint inhibitor therapy. Clinicians should characterize weakness, pain, swallowing, and breathing problems while considering possible overlapping myocarditis or neuromuscular complications. Because the condition can progress rapidly, timely assessment supports decisions about whether treatment interruption is appropriate and whether immunosuppressive therapy should begin.

Management may require interruption of the immune checkpoint inhibitor when clinically appropriate, followed by corticosteroid or other immunosuppressive treatment. The choice and urgency depend on the presentation, especially when weakness progresses or swallowing and breathing are affected. These measures aim to control immune-mediated muscle injury while clinicians reassess how safely cancer therapy can proceed.

ICI-related myositis matters in oncology because controlling toxicity must be balanced with ongoing cancer care. Once symptoms are recognized and managed, clinicians can reassess whether and how treatment may continue rather than assuming therapy must permanently stop. Attention to myocarditis and neuromuscular overlap is central to making continuation of cancer therapy safer.